'''Atagabalin''' ('''PD-0200,390''') is a drug developed by [[Pfizer]] and related to [[gabapentin]], which similarly binds to the α<sub>2</sub>δ [[calcium channel]]s ([[CACNA2D1|1]] and [[CACNA2D2|2]]).<ref name="pmid20005103">{{cite journal |vauthors=Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC |title=Synthesis and in vivo evaluation of bicyclic gababutins |journal=Bioorganic & Medicinal Chemistry Letters |volume=20 |issue=2 |pages=461–4 |date=January 2010 |pmid=20005103 |doi=10.1016/j.bmcl.2009.11.118 |url=}}</ref> It was under development as a treatment for [[insomnia]],<ref name="pmid19694735">{{cite journal |vauthors=Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G |title=Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit |journal=British Journal of Clinical Pharmacology |volume=68 |issue=2 |pages=174–80 |date=August 2009 |pmid=19694735 |pmc=2767279 |doi=10.1111/j.1365-2125.2009.03444.x |url=}}</ref><ref name="pmid21664606">{{cite journal |vauthors=Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA |title=Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology |journal=Brain Research |volume= 1401|issue= |pages= 1–9|date=May 2011 |pmid=21664606 |doi=10.1016/j.brainres.2011.05.025 |url=}}</ref><ref name="pmid21681607">{{cite journal |vauthors=Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO |title=Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models |journal=Pharmaceutical Research |volume= 28|issue= 10|pages= 2610–27|date=June 2011 |pmid=21681607 |doi=10.1007/s11095-011-0490-x |url=}}</ref> but was discontinued following unsatisfactory trial results.
